What the FDA labels say about taking them together
Selegiline and sertraline
Selegiline's FDA label of August 7, 2024 names sertraline in its warnings section, and sertraline's label names selegiline too. The sertraline label: “The concomitant use of SSRIs including ZOLOFT and MAOIs increases the risk of serotonin syndrome.”
Check it at the source: the selegiline FDA label on DailyMed (effective August 7, 2024, Rising Pharma Holdings, Inc.); the sertraline FDA label on DailyMed (effective August 8, 2023, Viatris Specialty LLC).
What does the selegiline label say about sertraline?
Selegiline label, warningsSimilar signs have been reported in some patients on the combination of selegiline (10 mg a day) and selective serotonin reuptake inhibitors including fluoxetine, sertraline and paroxetine.
Zelapar label (Bausch Health US, LLC, June 1, 2021), warnings and precautionsClinical studies of ZELAPAR did not allow concomitant use of any selective serotonin re-uptake inhibitor (e.g., fluoxetine-Prozac, fluvoxamine-Luvox, paroxetine-Paxil, sertraline, venlafaxine-Effexor, or nefazodone-Serzone) or any non-selective serotonin reuptake inhibiting antidepressant drug (except when taken at a low dose and only at night for the purpose of effective sleep) with ZELAPAR.
Emsam label (Viatris Specialty LLC, May 15, 2020), contraindicationsEMSAM (selegiline transdermal system) is contraindicated with selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine, sertraline, and paroxetine); serotonin and norepinephrine reuptake inhibitors (SNRIs, e.g., venlafaxine and duloxetine); the tricyclic antidepressants clomipramine and imipramine, the opiate analgesics meperidine, tramadol, methadone, pentazocine, and propoxyphene; and the antitussive agent dextromethorphan because of a risk of serotonin syndrome when EMSAM is used with these agents [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ].
Source: FDA drug label (Zelapar, NDA021479), Bausch Health US, LLC, effective June 1, 2021 (SPL set 380d7717-2a79-42f3-a712-efe5e7696ba0), via openFDA
Source: FDA drug label (Emsam, NDA021336), Viatris Specialty LLC, effective May 15, 2020 (SPL set b891bd9f-fdb8-4862-89c5-ecdd700398a3), via openFDA
Source: FDA drug label (Selegiline Hydrochloride), Rising Pharma Holdings, Inc., effective August 7, 2024 (SPL set 23c4481f-d150-40c6-addb-b3e454ca914f), via openFDA; the full label on DailyMed
What does the sertraline label say about selegiline?
Sertraline label, drug interactionsMonoamine Oxidase Inhibitors (MAOIs) Clinical Impact: The concomitant use of SSRIs including ZOLOFT and MAOIs increases the risk of serotonin syndrome. Intervention: ZOLOFT is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [See,, ]. Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue
Source: FDA drug label (Sertraline Hydrochloride, NDA020990), Mylan Pharmaceuticals Inc., effective September 15, 2024 (SPL set 1a58062b-e635-431a-908d-2651c6a4a21c), via openFDA
Source: FDA drug label (Zoloft), Viatris Specialty LLC, effective August 8, 2023 (SPL set fda754f6-d0f3-4dce-a17a-927d64f912f7), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Selegiline | Sertraline | |
|---|---|---|
| Labeled for | Parkinson's disease, Depression | Depression, Anxiety |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.756 per capsule 5 mg capsule | $0.0507 per tablet 100 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once